Patents by Inventor Tomoko Yasuhiro
Tomoko Yasuhiro has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11826363Abstract: A therapeutic agent for treatment of solid cancers, including, as an effective component, N-{5-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-pyridinyl}-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-3-quinolinecarboxamide, a pharmaceutically acceptable salt thereof, or a hydrate of the compound or the salt in combination with osimertinib or a pharmaceutically acceptable salt thereof. The combination of the present invention has strong antitumor effect and is therefore useful for treatment of solid cancers.Type: GrantFiled: October 12, 2018Date of Patent: November 28, 2023Assignees: ONO PHARMACEUTICAL CO., LTD., KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATIONInventors: Koichi Takayama, Tadaaki Yamada, Tomoko Yasuhiro, Kohei Tanaka
-
Publication number: 20200392110Abstract: A compound represented by general formula (I) has a strong Axl inhibitory activity by introducing a distinctive bicyclic structure in which a saturated carbon ring is fused to a pyridone ring, and can be a therapeutic agent for Axl-related diseases, for example, cancer such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glioma, kidney diseases, immune system diseases, and circulatory system diseasesType: ApplicationFiled: April 24, 2020Publication date: December 17, 2020Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Takayuki INUKAI, Jun TAKEUCHI, Tomoko YASUHIRO
-
Publication number: 20200330453Abstract: A therapeutic agent for treatment of solid cancers, including, as an effective component, N-{5-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-pyridinyl}-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-3-quinolinecarboxamide, a pharmaceutically acceptable salt thereof, or a hydrate of the compound or the salt in combination with osimertinib or a pharmaceutically acceptable salt thereof. The combination of the present invention has strong antitumor effect and is therefore useful for treatment of solid cancers.Type: ApplicationFiled: October 12, 2018Publication date: October 22, 2020Applicants: ONO PHARMACEUTICAL CO., LTD., KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATIONInventors: Koichi TAKAYAMA, Tadaaki YAMADA, Tomoko YASUHIRO, Kohei TANAKA
-
Publication number: 20200197385Abstract: A pharmaceutical composition for cancer treatment, comprising an Axl inhibitor and an anticancer drug (for example, a cytotoxic anticancer drug, a molecular target drug, an anti-CTLA-4 antibody, and the like), wherein the Axl inhibitor is a compound represented by the general formula (I): (wherein all of the symbols have the same meanings as set forth in the specification), a salt thereof, a solvate thereof, an N-oxide thereof, or a prodrug thereof, and which exhibits a strong antitumor effect, and therefore is useful for treatment of blood cancer and/or solid cancer.Type: ApplicationFiled: August 22, 2018Publication date: June 25, 2020Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Tomoko YASUHIRO, Kohei TANAKA
-
Patent number: 10676462Abstract: A compound represented by general formula (I) has a strong Axl inhibitory activity by introducing a distinctive bicyclic structure in which a saturated carbon ring is fused to a pyridone ring, and can be a therapeutic agent for Axl-related diseases, for example, cancer such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glioma, kidney diseases, immune system diseases, and circulatory system diseasesType: GrantFiled: August 14, 2019Date of Patent: June 9, 2020Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Takayuki Inukai, Jun Takeuchi, Tomoko Yasuhiro
-
Publication number: 20200171153Abstract: The present invention is directed to the combination therapy of an anti-CD20 antibody with a BTK inhibitor for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with a type I anti-CD20 antibody or an afucosylated humanized B-Ly1 antibody and a BTK inhibitor.Type: ApplicationFiled: November 11, 2019Publication date: June 4, 2020Inventors: Christian Klein, Toshio Yoshizawa, Tomoko Yasuhiro
-
Publication number: 20200002313Abstract: A compound represented by general formula (I) has a strong Axl inhibitory activity by introducing a distinctive bicyclic structure in which a saturated carbon ring is fused to a pyridone ring, and can be a therapeutic agent for Axl-related diseases, for example, cancer such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glioma, kidney diseases, immune system diseases, and circulatory system diseasesType: ApplicationFiled: August 14, 2019Publication date: January 2, 2020Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Takayuki INUKAI, Jun TAKEUCHI, Tomoko YASUHIRO
-
Patent number: 10501442Abstract: A compound represented by general formula (I) has a strong Axl inhibitory activity by introducing a distinctive bicyclic structure in which a saturated carbon ring is fused to a pyridone ring, and can be a therapeutic agent for Axl-related diseases, for example, cancer such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glioma, kidney diseases, immune system diseases, and circulatory system diseasesType: GrantFiled: December 31, 2018Date of Patent: December 10, 2019Assignee: ONO PHARMACEUTICALS CO., LTD.Inventors: Takayuki Inukai, Jun Takeuchi, Tomoko Yasuhiro
-
Publication number: 20190135785Abstract: A compound represented by general formula (I) has a strong Axl inhibitory activity by introducing a distinctive bicyclic structure in which a saturated carbon ring is fused to a pyridone ring, and can be a therapeutic agent for Axl-related diseases, for example, cancer such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glioma, kidney diseases, immune system diseases, and circulatory system diseasesType: ApplicationFiled: December 31, 2018Publication date: May 9, 2019Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Takayuki Inukai, Jun Takeuchi, Tomoko Yasuhiro
-
Publication number: 20190099413Abstract: A drug for cancer therapy characterized in that an Axl inhibitor and an immune checkpoint inhibitor (for example, an anti-PD-1 antibody) are administered in combination, wherein the Axl inhibitor is a compound represented by the general formula (I): (wherein in the formula, all of the symbols have the same meanings as defined in the specification), a salt thereof, a solvate thereof, an N-oxide thereof, or a prodrug thereof, and the combination exhibits a strong anti-tumor effect and, therefore, is useful for cancer therapy.Type: ApplicationFiled: February 24, 2017Publication date: April 4, 2019Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Kohei TANAKA, Tomoko YASUHIRO
-
Publication number: 20190054090Abstract: Provided herein are methods relating to a therapeutic strategy for treatment of cancer, including hematological malignancies. In particular, the methods include administration of a Btk inhibitor and a checkpoint inhibitor, including combinations in which the Btk inhibitor is 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one, or a pharmaceutically acceptable salt thereof, and the checkpoint inhibitor is selected from inhibitors of PD-1, PD-L1, and CTLA-4.Type: ApplicationFiled: September 30, 2016Publication date: February 21, 2019Inventors: Sriram Venkataraman, Daniel B. Tumas, Kohei Tanaka, Tomoko Yasuhiro, Toshio Yoshizawa
-
Patent number: 10208022Abstract: A compound represented by general formula (I) has a strong Axl inhibitory activity by introducing a distinctive bicyclic structure in which a saturated carbon ring is fused to a pyridone ring, and can be a therapeutic agent for Axl-related diseases, for example, cancer such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glioma, kidney diseases, immune system diseases, and circulatory system diseasesType: GrantFiled: May 10, 2018Date of Patent: February 19, 2019Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Takayuki Inukai, Jun Takeuchi, Tomoko Yasuhiro
-
Patent number: 10208034Abstract: A compound represented by general formula (I) and having a quinoline skeleton has a strong Axl inhibitory activity, and therefore the compound can be an agent for treating Axl-related diseases, for example, cancer such as acute myeloid leukemia, chronic myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glioma, kidney diseases, immune system diseases, and circulatory system diseases.Type: GrantFiled: December 24, 2015Date of Patent: February 19, 2019Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Takayuki Inukai, Jun Takeuchi, Tomoko Yasuhiro
-
Publication number: 20180353512Abstract: Provided herein are methods that relate to a therapeutic strategy for treatment of a B-cell malignancy. In particular, the methods include administration of a PI3K inhibitor and a BTK inhibitor.Type: ApplicationFiled: June 22, 2016Publication date: December 13, 2018Inventors: Helen Collins, Julie Di Paolo, Kathy Keegan, Ryohei Kozaki, Sarah Meadows, Cara Nelson, Christophe Queva, Srinivasan Ramanathan, Stacey Tannheimer, Daniel Tumas, Tomoko Yasuhiro, Toshio Yoshizawa
-
Publication number: 20180258072Abstract: A compound represented by general formula (I) has a strong Axl inhibitory activity by introducing a distinctive bicyclic structure in which a saturated carbon ring is fused to a pyridone ring, and can be a therapeutic agent for Axl-related diseases, for example, cancer such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glioma, kidney diseases, immune system diseases, and circulatory system diseasesType: ApplicationFiled: May 10, 2018Publication date: September 13, 2018Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Takayuki INUKAI, Jun TAKEUCHI, Tomoko YASUHIRO
-
Patent number: 9994549Abstract: A compound represented by general formula (I) has a strong Axl inhibitory activity by introducing a distinctive bicyclic structure in which a saturated carbon ring is fused to a pyridone ring, and can be a therapeutic agent for Axl-related diseases, for example, cancer such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glioma, kidney diseases, immune system diseases, and circulatory system diseasesType: GrantFiled: December 8, 2016Date of Patent: June 12, 2018Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Takayuki Inukai, Jun Takeuchi, Tomoko Yasuhiro
-
Publication number: 20170349583Abstract: A compound represented by general formula (I) and having a quinoline skeleton has a strong Axl inhibitory activity, and therefore the compound can be an agent for treating Axl-related diseases, for example, cancer such as acute myeloid leukemia, chronic myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glioma, kidney diseases, immune system diseases, and circulatory system diseases.Type: ApplicationFiled: December 24, 2015Publication date: December 7, 2017Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Takayuki INUKAI, Jun TAKEUCHI, Tomoko YASUHIRO
-
Publication number: 20170088542Abstract: A compound represented by general formula (I) has a strong Axl inhibitory activity by introducing a distinctive bicyclic structure in which a saturated carbon ring is fused to a pyridone ring, and can be a therapeutic agent for Axl-related diseases, for example, cancer such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glioma, kidney diseases, immune system diseases, and circulatory system diseasesType: ApplicationFiled: December 8, 2016Publication date: March 30, 2017Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Takayuki INUKAI, Jun TAKEUCHI, Tomoko YASUHIRO
-
Patent number: 9586967Abstract: A compound represented by the general formula (1) has a pyridone ring structure introduced into a pyrrolo pyrimidine skeleton, so that the compound has a strong Axl inhibitory activity. Consequently, the compound can be used as a therapeutic agent for Axl-related diseases including cancers such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glioma, kidney diseases, immune system diseases, and circulatory system diseases.Type: GrantFiled: November 6, 2014Date of Patent: March 7, 2017Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Takayuki Inukai, Jun Takeuchi, Tomoko Yasuhiro, Mark Allan Wolf, Vijay Dattaram Pawar, Anjan Chakrabarti, Santhosh Kumar Chittimalla
-
Patent number: 9573935Abstract: A compound represented by general formula (I) has a strong Axl inhibitory activity by introducing a distinctive bicyclic structure in which a saturated carbon ring is fused to a pyridone ring, and can be a therapeutic agent for Axl-related diseases, for example, cancer such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glioma, kidney diseases, immune system diseases, and circulatory system diseases.Type: GrantFiled: July 23, 2014Date of Patent: February 21, 2017Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Takayuki Inukai, Jun Takeuchi, Tomoko Yasuhiro